Olmsted Medical Center:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Olmsted Medical Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9330
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Olmsted Medical Center (OMC) is a healthcare service provider that offers patient care services. The center offers services in the areas of general surgery, podiatry, pain management, dermatology, plastic surgery, inpatient dietary services, pediatrics, diabetes education, neurology, psychiatry, psychology, nutrition education and weight loss surgery, among others. It also offers birth center, laboratory services, radiology, diagnostic imaging, rheumatology, endocrinology, rehabilitation services, ENT, respiratory therapy, emergency medicine, audiology, anticoagulation clinic and others. The center operates in Chatfield, St Charles, Cannon Falls, Byron, Preston, Spring Valley and others. OMC is headquartered in Rochester, Minnesota, the US.

Olmsted Medical Center – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Olmsted Medical Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deal Details 9
Debt Offering 9
Olmsted Completes Public Offering Of Series 2010 Bonds Due 2020 For US$4.2 Million 9
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2015 For US$0.5 Million 10
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2016 For US$0.63 Million 11
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2017 For US$0.65 Million 12
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2018 For US$0.68 Million 13
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2019 For US$0.71 Million 14
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2020 For US$0.75 Million 15
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2021 For US$0.79 Million 16
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2022 For US$0.83 Million 17
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2023 For US$0.87 Million 18
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2024 For US$0.9 Million 19
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2025 For US$0.9 Million 20
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2026 For US$0.96 Million 21
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2027 For US$0.99 Million 22
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2028 For US$1.04 Million 23
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2029 For US$1.1 Million 24
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2033 For US$4.9 Million 25
Olmsted Medical Center – Key Competitors 26
Olmsted Medical Center – Key Employees 27
Olmsted Medical Center – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Olmsted Medical Center, Pharmaceuticals & Healthcare, Key Facts 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Olmsted Medical Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Olmsted Completes Public Offering Of Series 2010 Bonds Due 2020 For US$4.2 Million 9
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2015 For US$0.5 Million 10
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2016 For US$0.63 Million 11
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2017 For US$0.65 Million 12
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2018 For US$0.68 Million 13
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2019 For US$0.71 Million 14
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2020 For US$0.75 Million 15
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2021 For US$0.79 Million 16
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2022 For US$0.83 Million 17
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2023 For US$0.87 Million 18
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2024 For US$0.9 Million 19
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2025 For US$0.9 Million 20
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2026 For US$0.96 Million 21
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2027 For US$0.99 Million 22
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2028 For US$1.04 Million 23
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2029 For US$1.1 Million 24
Olmsted Completes Public Offering Of Series 2013 Bonds Due 2033 For US$4.9 Million 25
Olmsted Medical Center, Key Competitors 26
Olmsted Medical Center, Key Employees 27
Olmsted Medical Center, Other Locations 28
Olmsted Medical Center, Subsidiaries 29

List of Figures
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Olmsted Medical Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★海外企業調査レポート[Olmsted Medical Center:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pernod Ricard SA:戦略・SWOT・企業財務分析
    Pernod Ricard SA - Strategy, SWOT and Corporate Finance Report Summary Pernod Ricard SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Blade Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Blade Therapeutics Inc (Blade Therapeutics) is a biopharmaceutical company which develops novel anti-fibrotic therapies to treat various fibrotic disorders. Its lead program is a small molecule inhibitor targeting an intracellular cysteine protease associated with fibrosis across diverse ind …
  • Duravit AG:企業の戦略・SWOT・財務情報
    Duravit AG - Strategy, SWOT and Corporate Finance Report Summary Duravit AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Armune BioScience Inc:製品パイプライン分析
    Summary Armune BioScience Inc (Armune) is a medical device company that develops and commercializes molecular diagnostic and prognostic tests. The company uses genomics and proteomics in cancer to identifying specific sets of genes or proteins. It develops protein signature based diagnostic tests fo …
  • Forestar Group Inc:企業の戦略・SWOT・財務分析
    Forestar Group Inc - Strategy, SWOT and Corporate Finance Report Summary Forestar Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • tella Inc (2191):製薬・医療:M&Aディール及び事業提携情報
    Summary Tella Inc (Tella) is a drug development company that develops vaccines for cancer treatment. The company offers dendritic cell vaccine therapy which develops dendritic cells to convey the information on cancer markers to lymphocytes and increase the dendritic cell population and strengthen t …
  • Hainan Airlines Co., Ltd.:企業のM&A・事業提携・投資動向
    Hainan Airlines Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hainan Airlines Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Galectin Therapeutics Inc (GALT):企業の財務・戦略的SWOT分析
    Summary Galectin Therapeutics Inc (Galectin Therapeutics), formerly Pro-Pharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company provides products such as GR-MD-02, GM-CT-01, and others. Its GR-MD-02 is a drug c …
  • Shimano Inc. (7309):企業の財務・戦略的SWOT分析
    Shimano Inc. (7309) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • 01 Communique (ONE):企業の財務・戦略的SWOT分析
    Summary 01 Communique (Communique) is a technology company that develops and delivers integrated communication software and services. The company's products include I'm InTouch meeting, I'm InTouch, I'm OnCall and Communicate!. Communique I'm InTouch provides a secure and easy to use PC remote acces …
  • TClarke Plc (CTO):企業の財務・戦略的SWOT分析
    TClarke Plc (CTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Orsted AS (ORSTED):電力:M&Aディール及び事業提携情報
    Summary Orsted AS (Orsted) formerly Dong Energy A/S, is an integrated energy company that procures, produces, distributes and trades energy and energy related products. It generates electricity and heat using conventional fuel and wind energy sources. The company also develops, constructs, owns and …
  • PFSweb Inc (PFSW):企業の財務・戦略的SWOT分析
    Summary PFSweb Inc (PFSweb) is an eCommerce solutions provider. Its various services include agency services, marketing services, technology and financial services. The company offers solutions for omnichannel operations, technology ecosystem, and strategic commerce consulting. Its technology ecosys …
  • Aramark Services Inc (ARMK):企業の財務・戦略的SWOT分析
    Aramark Services Inc (ARMK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • United Orthopedic Corp (4129):医療機器:M&Aディール及び事業提携情報
    Summary United Orthopedic Corp (UOC) is a medical device company that designs, manufactures and distributes orthopedic implants and instrument sets. The company provides product categories such as knee replacement systems, hip replacement systems, and oncology products, among others. It offers hip r …
  • Olin Corp (OLN):企業の財務・戦略的SWOT分析
    Olin Corp (OLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • AECOM (ACM):企業の財務・戦略的SWOT分析
    AECOM (ACM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the poten …
  • RedHill Biopharma Ltd (RDHL):企業の財務・戦略的SWOT分析
    RedHill Biopharma Ltd (RDHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Unity Biotechnology Inc (UBX):製薬・医療:M&Aディール及び事業提携情報
    Summary Unity Biotechnology Inc (Unity Biotechnology), formerly Forge Inc is a biotechnology company that researches, develops and commercializes therapeutics for the treatment of age-related diseases. The company focuses on the development of senolytic medicines to eliminate senescent cells. The co …
  • Mobile Telesystems:企業の戦略・SWOT・財務情報
    Mobile Telesystems - Strategy, SWOT and Corporate Finance Report Summary Mobile Telesystems - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆